This application contains a Sequence Listing entitled NREL_20-137_ST25.txt, filed herewith, that is 61,440 bytes in size and was created on 2 Nov. 2023.
Energy demand continues to rise along with CO2 emissions. Carbon Capture and Storage (CCS) plays a significant role in reducing CO2 emissions produced from the use of fossil fuels in electricity generation and industrial processes. Bioenergy with Carbon Capture and Storage (BECCS) combines the use of biopower with greenhouse gas mitigating technology to produce energy with net-negative emissions. However, today's capture technologies are not cost-effective. Most current CCS processes rely on carbon scrubbing of flue gases with solvents like monoethanolamine (MEA) which requires energy intensive heating and cooling of the MEA to capture and release the CO2 generated in combustion. In addition, the solvent is corrosive and suffers degradation by other species present in gas mixtures. There is a need for alternative novel scrubbing techniques that incorporate biological solutions for capturing CO2 to improve the cost of carbon capture.
Carbonic anhydrases (CAs) are an example of convergent evolution where at least five distinct families of enzymes catalyze the same reaction but do not share significant sequence similarity or fold. Most but not all families of CA have been characterized structurally.
The chemical and enzymatic properties of CAs, like specific activity, thermal stability, and chemical stability vary greatly and have been previously targeted for improvement in industrial applications.
In an aspect, disclosed herein is a non-naturally occurring carbonic anhydrase comprising at least one mutation that results in the substitution of at least one cysteine for at least one amino acid in a naturally occurring carbonic anhydrase; and wherein the non-naturally occurring carbonic anhydrase has increased activity at a temperature of greater than about 60 degrees Celsius when compared to the naturally occurring carbonic anhydrase. In an embodiment, the non-naturally occurring carbonic anhydrase has increased activity that is for more than about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44 hours, 48 hours, and 92 hours. In an embodiment, the non-naturally occurring carbonic anhydrase has increased activity that is at a temperature greater than 65, 70, 75, 80, 85 or 90 degrees Celsius. In an embodiment, the non-naturally occurring carbonic anhydrase has a nucleotide sequence encoding the non-naturally occurring carbonic anhydrase that comprises a sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24 and SEQ ID NO: 26. In an embodiment, the non-naturally occurring carbonic anhydrase has an amino acid sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23 and SEQ ID NO: 25.
In an aspect, disclosed herein is a method for CO2 separation and CO2 capture comprising the step of reacting CO2 with a non-naturally occurring carbonic anhydrase comprising at least one mutation that results in the substitution of at least one cysteine for at least one amino acid in a naturally occurring carbonic anhydrase; and wherein the non-naturally occurring carbonic anhydrase has increased activity at a temperature of greater than about 60 degrees Celsius when compared to the naturally occurring carbonic anhydrase. In an embodiment, the method contains the step of reacting CO2 with non-naturally occurring carbonic anhydrase is for more than about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44 hours, 48 hours, and 92 hours. In an embodiment, the method contains the step of reacting CO 2 with the non-naturally occurring carbonic anhydrase is at a temperature greater than 65, 70, 75, 80, 85 or 90 degrees Celsius. In an embodiment, the the non-naturally occurring carbonic anhydrase comprises a nucleotide sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24 and SEQ ID NO: 26. In an embodiment, the non-naturally occurring carbonic anhydrase comprises an amino acid sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID
NO: 23 and SEQ ID NO: 25.
In an aspect, disclosed herein is a system for CO2 separation and CO2 capture comprising non-naturally occurring carbonic anhydrases comprising at least one mutation that results in the substitution of at least one cysteine for at least one amino acid in a naturally occurring carbonic anhydrase; and wherein the non-naturally occurring carbonic anhydrase has increased activity at a temperature of greater than about 60 degrees Celsius when compared to the naturally occurring carbonic anhydrase; and wherein the system further comprises a support wherein the with the non-naturally occurring carbonic anhydrases are immobilized to the support; and wherein the non-naturally occurring carbonic anhydrases are contacted with CO2. In an embodiment, the non-naturally occurring carbonic anhydrase has increased activity for more than about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44 hours, 48 hours, and 92 hours. In an embodiment, the non-naturally occurring carbonic anhydrases react with CO2 at a temperature greater than 65, 70, 75, 80, 85 or 90 degrees Celsius. In an embodiment, the CO2 results from the combustion of fossil fuels or biomass. In an embodiment, the system further comprises a carbon capture unit wherein the carbon capture unit comprises an immobilized biocatalyst comprising an amino acid sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23 and SEQ ID NO: 25.
Other objects, advantages, and novel features of the present invention will become apparent from the following detailed description of the invention when considered in conjunction with the accompanying drawings.
Being one of the fastest enzymes known in nature, carbonic anhydrase (CA) catalyzes the interconversion between CO2 and bicarbonate which accelerates the capture of CO2 by serving as a catalyst in alkaline capture solvents with slow absorption kinetics. The enzyme accelerated process allows use of more benign and sustainable solvents with low regeneration energy thus reducing energy consumption.
Disclosed herein are CA enzyme candidates with improved catalytic activity, thermostability and solvent compatibility and developed new enzyme immobilization techniques for improving the enzyme longevity and tested more benign and sustainable solvents accelerated by CA for CO2 capture. The improved enzyme properties together with the novel immobilization technology with selected solvents have the potential to significantly reduce the cost and the energy requirement for CO2 capture.
Disclosed herein are optimized, highly active and thermostable carbonic anhydrase enzymes, which are needed for testing in a novel and low energy CO2 scrubbing process. CA is gaining credibility as an efficient catalyst for significantly enhancing reactive CO2 absorption in low energy solvents. To overcome the high energy requirement of traditional monoethanolamine (MEA)-based CO2 scrubbing process, disclosed herein are methods, compositions and systems used to develop more efficient CO2 scrubbing technology by: 1) improving the robustness of CA, including tolerance to high temperature, high solvent concentration and high pH; 2) improving CA longevity using biodegradable enzyme-entrapping polymeric structures (BEEPS); and 3) utilizing environmentally friendly solvents to improve process sustainability.
The most studied CA family currently is alpha-class of CAs with at least five members of the family being characterized biochemically and structurally:
While active site organization of the listed above alpha-class CAs is suited for an independent monomeric function, it seems that all examples (except for TaCA) exist as dimers in the solution, see
In, for example
In an embodiment, disclosed herein are novel protein dimers of alpha-CAs via one or more covalent disulfide bonds designed at the dimerization interface via one or more single-point mutations, replacing a native amino acid residue of the enzyme with cysteine. The exact locations of the single-point mutation may be used in alpha-CAs from different species. Three locations for the intermolecular disulfides were designed in the first round, in an embodiment, PmaCA numbering (including signal peptide, SP) is reflected in
In an embodiment, mutants 1, 2, 3, and 2+3 combination were introduced in PmaCA and 2, 3, and 2+3 in SazCA. For SazCA mutant 1 is Gly210Cys+Asn246Cys (numbering according to the full-length sequence including signal peptide), mutant 2 is Ala71Cys, mutant 3 is Ser199Cys+Ser247Cys. Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35° C. and 45° C. temperatures. Culturing media containing secreted enzymes (broth) was collected, cells were spun down and removed. All enzymes were subjected to the prolonged incubation at 90° C. in form of the broth. Samples were taken out at 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44-48 hours, and 92 hours. Samples were immediately cooled down to 0° C. and the enzyme activity was tested by Wilbur-Anderson method using colorimetric assay.
Assay description: In an embodiment, an assay is performed on ice at 0° C.-1° C. temperature. All solutions are chilled on ice until the desired temperature is reached. 1 mL of the 20 mM Tris buffer at pH 8.3 was mixed with 0.1 mL pH indicator Bromthymol Blue (BTB). Ten uL (0.01 mL) of broth containing enzyme was added to the mix (nothing added for the control). Then, 1 mL of water fully saturated with CO2 was added and the stopwatch was started. When BTB changed color from blue to yellow indicating pH dropping below 6.3, stopwatch was stopped. Uncatalyzed reaction time (To) is longer than catalyzed reaction time (Tc) when an activity catalyst is present. Activity in Wilbur-Anderson units is calculated as WAU=(To−Tc)/Tc.
For the comparison of different enzymes broth activity, this WAU value is then normalized for the dilution factor (DF=Vtot/Vbroth where Vtot is a total reaction volume and Vbroth is the volume of broth added) and optical density of the broth (OD), so the units to compare would be WAU*DF/OD.
For the measurement of retained activity, WAU value of each enzyme at start is taken as 100% for that particular enzyme, and WAU values obtained after various incubation times are compared to the initial WAU activity value.
As an example, results for PmaCA enzymes set are depicted in
To be effective for CO2 sequestration, CA enzymes need to withstand harsh process conditions, high temperature, high pH, high solvent conditions and tolerance of gas and process contaminants. In an embodiment, the non-naturally occurring CA enzymes disclosed herein 1) improve enzyme robustness including thermotolerance of CA enzymes with fast CO2 absorption rate, thermostability and solvent compatibility; 2) improve CA longevity using biodegradable enzyme-entrapping polymeric structures (BEEPS); and 3) utilize compatible environmentally friendly solvents to improve process sustainability with lower energy requirement. Thus, disclosed herein are engineered, non-naturally occurring CA enzymes with improved properties including catalytic activity, thermostability and solvent compatibility.
In an embodiment, a large quantity of the improved CA enzyme candidates is needed for fabricating sufficient immobilized biocatalyst materials using enzyme immobilization technology and further testing at the bench-scale integrated carbon capture unit with selected more benign and sustainable solvents with low regeneration energy. In an embodiment, the system (with an internal diameter of 7.6 cm, a packing height of approximately 2 m) was outfitted with instrumentation to allow comprehensive data gathering on temperature profile along the absorber and stripper column to calculate mass transfer flux and regeneration energy consumption, optimize the enzyme production process for scaling-up the production of the improved CA enzyme candidates; and produce up to 100 g of protein for fabricating immobilized biocatalyst and testing at the integrated carbon capture unit. The improved enzyme properties together with the novel immobilization technology with selected solvents provide substantial reduction of the energy requirement and cost for CO2 capture. In an embodiment, the compositions, methods and systems disclosed herein provide alternative CO2 capture technologies which can be deployed in many industrial applications for capturing CO2 from biopower and fossil-based power plants.
The data graphically depicted in
The data depicted in
The data depicted in
The data depicted in
indicates data missing or illegible when filed
B. subtilis strain WB800N strain was obtained from MoBiTec GmbH (Gottingen, Germany), and used as the host strain for extracellular expression of CAs. WB800N strain was an eightfold extracellular protease deficient derivative of strain 168, with genotype of nprE aprE epr bpr mpr::ble nprB::bsr Δvpr wprA::hyg cm::neo; NeoR (i.e. carries resistance to neomycin). The competent cells of WB800N were prepared according to the technical guide provided by the above company.
Bacillus expression vector pHT43 was obtained from MoBiTec GmbH (Gottingen, Germany).
The signal peptide of Bacillus licheniformis alpha-amylase (i.e. AmyL; uniprot ID, P06278) is a 29 aa signal peptide named as SPamyL, MKQQKRLYARLLTLLFALIFLLPHSAAAA (SEQ ID NO: 35); this signal peptide was used for the expression and secretion of CAs.
The sequence of each CA gene was codon-optimized using B. subtilis codon usage frequency and synthesized by GenScript Inc (Piscataway, New Jersey); it had KpnI site at 5′ end, and stop codon-XbaI (taatctaga) at 3′ end, and was composed of 87 nucleotides coding for the 29 aa of signal peptide SPamyL, followed by the codon-optimized CA gene sequence, as disclosed herein in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.
For the subcloning, digest the above synthesized gene with KpnI-XbaI, and linked into KpnI-XbaI cut pHT43 vector. The obtained plasmids were used for transformation as described below.
These above plasmids plus the empty vector pTH43 were transformed into B. subtilis WB800N competent cells, using the procedure according to the technical guide provided by the above company. The obtained strains were listed in the below table.
Since the plasmids we built contain signal peptide SPamyL, the recombinant CAs were expected to be secreted into the medium. To test the secretion of CAs, obtained transformants were cultured. Briefly, inoculate the recombinant B. subtilis strains from plate or glycerol storage into 5 mL fresh 2xYT medium (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, final pH 7.0) supplemented with neomycin 10 μg/mL and chloramphenicol (5 μg/mL), and cultured in a shaker at 35° C., 210 rpm. Inoculated the above seed culture into 20 mL fresh 2xYT medium supplemented with neomycin 10 μg/mL and chloramphenicol (5 μg/mL) in a 125-mL flask to an OD600 of 0.15. The cultures were grown in a shaker at 35° C., 210 rpm until the OD600 reached 0.7-0.8, then it was induced with 1 mM IPTG and 0.5 mM ZnSO4, by which two aliquots of samples being collected and defined as T0: 100 uL and 1 mL). The cultures were continued to grow in a shaker at 35° C. and 130 rpm.
Similarly, three aliquots were collected at 6 and 12 h after the induction (defined as T6 and T12 samples): 100 μL and 1 mL. These T0 and T12 samples were centrifuged at 12,000 rpm, 10 min, 4° C. to separate the supernatants and pellets. While 100 μL supernatant was mixed with 33 μL 4×LDS sample buffer, the pellets from 100 uL culture were suspended in 133 μL 1×LDS sample buffer; both being heated at 95° C. for 5 min, followed by centrifugation at 12,000 rpm for 2 min to remove any debris. For these protein samples, 20 μL of each preparation was analyzed with SDS-PAGE.
The expression and secretion of CA proteins by the mutants were also examined after being induced at 30, 35 and 45° C. for 12 hours. The procedures for seed culture preparation, the inoculation into the fresh 2XYT and the initial culturing to OD600 of 0.7-0.8 at the default 35° C. were the same as described in the above section of “Expression and secretion of CA proteins induced at the default 35° C.”. When the OD600 reached 0.7-0.8, 1 mM IPTG and 0.5 mM ZnSO4 (final concentration) were added into 20 mL culture in 125-mL flasks. The flasks were transferred to different shakers set at designated either 30° C., or 35° C., or 45° C., with a speed of 130 rpm for 12 hours. The samples were harvested and centrifuged as described above, with the supernatants being collected and stored at 4° C. until being analyzed for the CA activity, heat treatment and thermostability analyses.
To test if the supplements of cysteine or diamide has any impacts on the folding, secretion and functionality of CA proteins, the expression and secretion of CA proteins by the mutants were investigated after being induced at OD600 of 0.7-0.8 with a mixture of IPTG and ZnSO4 without (as the control) or with cysteine or diamide, using the final concentrations as listed below, followed by continuing shaking at 130 rpm at designated 30° C., or 35° C., or 45° C. for 12 hours.
Treatments with cysteine or diamide supplements (with final concentration added into the medium at OD600 of 0.7-0.8):
By default, the cysteine stock was freshly prepared unless it was indicated otherwise. The diamide stock also was also freshly prepared.
SDS-PAGE analysis of the cell supernatants reveal that we have successfully expressed CA6FL as a representative CA with signal peptide SPamyL, Furthermore, 6 h of IPTG induction at 35° C. is sufficient to lead CA6FL expression and secretion at substantial levels, while a longer IPTG induction time to 12 hours led to higher expression and secretion levels of CA6FL (
In an embodiment, elevated temperature leads to better CA expression in B. subtilis. Experiment 1: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 30° C., 35° C., and 45° C. for PmaCA (CA3), see
Experiment 2: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35° C., and 45° C. for LogaCA, see
Experiment 3: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35° C., and 45° C. for SspCA (CA5), see
Experiment 4: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35° C., and 45° C. for SazCA (CA6), see
In an embodiment, addition of free cysteine to the expression media leads to the better CA expression. Experiment 5: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 45° C. for PmaCA (CA3) with and without addition of the cysteine, see
Experiment 6: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 45° C. for PmaCA (CA3) with and without addition of the cysteine, see
In an embodiment, addition of diamide to the expression media leads to the improved CA expression. Experiment 7: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 45° C. for PmaCA (CA3) with and without addition of the diamide, see
The following sequences are embodiments of amino acid and nucleotide sequences representing the genes encoding for engineered CAs disclosed herein.
SEQ ID NO:1 and SEQ ID NO: 2
SEQ name: SPamyL-PmaCA-CA3
LENGTH: 253 for PRT; 762 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3 PRT from Persephonella marina. Synthetic for DNA
SEQ ID NO:3 and SEQ ID NO: 4
SEQ name: SPamyL-PmaCA-CA3mut1
LENGTH: 253 for PRT; 762 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut1 modified from Persephonella marina.
SEQ ID NO: 5 and SEQ ID NO: 6
SEQ name: SPamyL-PmaCA-CA3mut2
LENGTH: 253 for PRT; 762 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut2 modified from Persephonella marina.
SEQ ID NO: 7 and SEQ ID NO: 8
SEQ name: SPamyL-PmaCA-CA3mut3
LENGTH: 253 for PRT; 762 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut3 modified from Persephonella marina.
SEQ ID NO: 9 and SEQ ID NO: 10
SEQ name: SPamyL-PmaCA-CA3mut23
LENGTH: 253 for PRT; 762 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut23 modified from Persephonella marina.
SEQ ID NO: 11 and SEQ ID NO: 12
SEQ name: SPamyL-LOGACA-CA4
LENGTH: 255 for PRT; 768 for DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4 from deep sea thermal vent.
SEQ ID NO: 13 and SEQ ID NO: 14
SEQ name: SPamyL-LOGACA-CA4mut2
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4mut2 modified from deep sea thermal vent.
SEQ ID NO: 15 and SEQ ID NO: 16
SEQ name: SPamyL-LOGACA-CA4mut3
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4mut3 modified from deep sea thermal vent.
SEQ ID NO: 17 and SEQ ID NO: 18
SEQ name: SPamyL-LOGACA-CA4mut23
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4mut23 modified from deep sea thermal vent.
SEQ ID NO: 19 and SEQ ID NO: 20
SEQ name: SPamyL-SspCA-CA5
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5 from Sulfurihydrogenibium sp. strain YO3AOP1.
SEQ ID NO: 21 and SEQ ID NO: 22
SEQ name: SPamyL-SspCA-CA5mut2
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5mut2 modified from Sulfurihydrogenibium sp. strain YO3AOP1.
SEQ ID NO: 23 and SEQ ID NO: 24
SEQ name: SPamyL-SspCA-CA5mut3
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5mut3 modified from Sulfurihydrogenibium sp. strain YO3AOP1.
SEQ ID NO: 25 and SEQ ID NO: 26
SEQ name: SPamyL-SspCA-CA5mut23
LENGTH: 255 for PRT; 768 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5mut23 modified from Sulfurihydrogenibium sp. strain YO3AOP1.
SEQ ID NO: 27 and SEQ ID NO: 28
SEQ name: SPamyL-SazCA-CA6FL
LENGTH: 266 for PRT; 801 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FL from Sulfurihydrogenibium azorense
SEQ ID NO: 29 and SEQ ID NO: 30
SEQ name: SPamyL-SazCA-CA6FLmut2
LENGTH: 266 for PRT; 801 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FLmut2 modified from Sulfurihydrogenibium azorense
SEQ ID NO: 31 and SEQ ID NO: 32
SEQ name: SPamyL-SazCA-CA6FLmut3
LENGTH: 266 for PRT; 801 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FLmut3 modified from Sulfurihydrogenibium azorense
SEQ ID NO: 33 and SEQ ID NO: 34
SEQ name: SPamyL-SazCA-CA6FLmut23
LENGTH: 266 for PRT; 801 for DNA
TYPE: PRT; DNA
ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FLmut23 modified from Sulfurihydrogenibium azorense
The foregoing discussion and examples have been presented for purposes of illustration and description. The foregoing is not intended to limit the aspects, embodiments, or configurations to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the aspects, embodiments, or configurations are grouped together in one or more embodiments, configurations, or aspects for the purpose of streamlining the disclosure. The features of the aspects, embodiments, or configurations, may be combined in alternate aspects, embodiments, or configurations other than those discussed above. This method of disclosure is not to be interpreted as reflecting an intention that the aspects, embodiments, or configurations require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment, configuration, or aspect. While certain aspects of conventional technology have been discussed to facilitate disclosure of some embodiments of the present invention, the Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass one or more of the conventional technical aspects discussed herein. The following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate aspect, embodiment, or configuration.
This application is a national phase entry under 35 U.S.C. § 371 and claims priority to PCT application number PCT/US/2022/017205 filed on 22 Feb. 2022. PCT/US/2022/017205 claims priority under 35 U.S.C. § 119 to U.S. provisional patent application No. 63/151,506 filed on 19 Feb. 2021 and 63/174,337 filed on 13 Apr. 2021, the contents of which are hereby incorporated in their entirety.
The United States Government has rights in this invention under Contract No. DE-AC36-08G028308 between the United States Department of Energy and the Alliance for Sustainable Energy, LLC, the Manager and Operator of the National Renewable Energy Laboratory.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US22/17205 | 2/22/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63174337 | Apr 2021 | US | |
63151506 | Feb 2021 | US |